Pierre-Luc Boudreault
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pierre-Luc Boudreault has a total of 320 co-authors. Here are the top co-authors by number of shared publications:
- Philippe Sarret
Université de Sherbrooke
13 shared publications - Antoine Désilets
Université de Sherbrooke
10 shared publications - Richard Leduc
Université de Sherbrooke
10 shared publications - Michael Desgagné
Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
9 shared publications Ulrike Froehlich
9 shared publications- Sára Ferková
Department of Pharmacology and Physiology Faculty of Medicine and Health Sciences Institut de Pharmacologie de Sherbrooke Université de Sherbrooke 3001, 12e Avenue Nord J1H 5N4 Sherbrooke Québec Canada
8 shared publications
Latest Publications
- Open Access
TMPRSS6 Cleavage of β-Klotho Modulates FGF19 Signaling
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent liver disorder worldwide, yet therapeutic options remain limited. TMPRSS6, a liver serine protease best known for its role in iron homeostasis, has recently emerged as a potential therapeutic target for MASLD. However, the molecular mechanisms linking TMPRSS6 to hepatic lipid metabolism remain incompletely understood. To identify novel TMPRSS6 substrates, we performed extracellular proteomic analyses of TMPRSS6-overexpressing cells. Among the proteins identified, β-klotho (KLB), a co-receptor required for FGF19 and FGF21 signaling, emerged as a compelling candidate substrate. We demonstrate that TMPRSS6 interacts with KLB and promotes its proteolytic shedding in a catalytic activity-dependent manner. Functionally, TMPRSS6 reduced full-length KLB abundance at the cell surface and attenuated FGF19-dependent FGFR4 signaling in a heterologous expression system. Together, these findings identify KLB as a novel functional substrate of TMPRSS6, providing a mechanistic framework through which this protease may influence hepatic lipid metabolism. These results provide a rationale for investigating the regulation of KLB and other candidate substrates by TMPRSS6 in physiological models and further support its evaluation as a therapeutic target for MASLD.
Open AccessTMPRSS6 Cleavage of β-Klotho Modulates FGF19 Signaling
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent liver disorder worldwide, yet therapeutic options remain limited. TMPRSS6, a liver serine protease best known for its role in iron homeostasis, has recently emerged as a potential therapeutic target for MASLD. However, the molecular mechanisms linking TMPRSS6 to hepatic lipid metabolism remain incompletely understood. To identify novel TMPRSS6 substrates, we performed extracellular proteomic analyses of TMPRSS6-overexpressing cells. Among the proteins identified, β-klotho (KLB), a co-receptor required for FGF19 and FGF21 signaling, emerged as a compelling candidate substrate. We demonstrate that TMPRSS6 interacts with KLB and promotes its proteolytic shedding in a catalytic activity-dependent manner. Functionally, TMPRSS6 reduced full-length KLB abundance at the cell surface and attenuated FGF19-dependent FGFR4 signaling in a heterologous expression system. Together, these findings identify KLB as a novel functional substrate of TMPRSS6, providing a mechanistic framework through which this protease may influence hepatic lipid metabolism. These results provide a rationale for investigating the regulation of KLB and other candidate substrates by TMPRSS6 in physiological models and further support its evaluation as a therapeutic target for MASLD.
- Open Access
- 4 July 2026
- Published by Elsevier in European Journal of Medicinal Chemistry Reports
- Vol. 17
Beyond arginine count: Rational engineering of amphipathic macrocyclic CPPs with enhanced intracellular delivery and endosomal escape
- 4 July 2026
- Published by Elsevier in European Journal of Medicinal Chemistry Reports
- Vol. 17
Open AccessBeyond arginine count: Rational engineering of amphipathic macrocyclic CPPs with enhanced intracellular delivery and endosomal escape
- Open Access
- 15 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (12) , 14156-14173
Structure-Guided Design of Proteomimetics Targeting the SARS-CoV-2 S-RBD/hACE2 Interface
The SARS-CoV-2 Spike receptor-binding domain (S-RBD)/hACE2 interaction represents a challenging protein-protein interaction (PPI) target due to its large, shallow binding interface. Here, in silico alanine mutagenesis guided the structure-based design of constrained peptidomimetics that reproduce key hACE2 recognition elements. α1-helix-derived mimetics (Glu23-Ser44) were stabilized using peptide stapling strategies, while antiparallel β-sheet mimetics (Thr347-Leu359) were generated through head-to-tail macrocyclization incorporating a d-Pro/l-Pro motif. Covalent linkage of these two secondary structure mimetics yielded proteomimetic 28, designed to preserve the spatial organization of the hACE2 binding interface. Compound 28 selectively binds SARS-CoV-2 S-RBD and disrupts the S-RBD/hACE2 interaction in biophysical and cellular assays, inhibiting pseudovirus entry (IC50 of 6.6 μM). Importantly, 28 displays high stability in lung epithelial models (t1/2 > 24 h) and low epithelial permeability (Papp = 2.03 × 10-8 cm·s-1), supporting its potential for intranasal antiviral delivery. These findings establish a proof-of-concept for proteomimetics as promising inhibitors of challenging PPIs.
- 15 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (12) , 14156-14173
Open AccessStructure-Guided Design of Proteomimetics Targeting the SARS-CoV-2 S-RBD/hACE2 Interface
The SARS-CoV-2 Spike receptor-binding domain (S-RBD)/hACE2 interaction represents a challenging protein-protein interaction (PPI) target due to its large, shallow binding interface. Here, in silico alanine mutagenesis guided the structure-based design of constrained peptidomimetics that reproduce key hACE2 recognition elements. α1-helix-derived mimetics (Glu23-Ser44) were stabilized using peptide stapling strategies, while antiparallel β-sheet mimetics (Thr347-Leu359) were generated through head-to-tail macrocyclization incorporating a d-Pro/l-Pro motif. Covalent linkage of these two secondary structure mimetics yielded proteomimetic 28, designed to preserve the spatial organization of the hACE2 binding interface. Compound 28 selectively binds SARS-CoV-2 S-RBD and disrupts the S-RBD/hACE2 interaction in biophysical and cellular assays, inhibiting pseudovirus entry (IC50 of 6.6 μM). Importantly, 28 displays high stability in lung epithelial models (t1/2 > 24 h) and low epithelial permeability (Papp = 2.03 × 10-8 cm·s-1), supporting its potential for intranasal antiviral delivery. These findings establish a proof-of-concept for proteomimetics as promising inhibitors of challenging PPIs.
- Open Access
Profiling crystal engineered ligands for targeting treatment resistant androgen receptors
Prostate cancer (PCa) is one of the principal contributors to health burden in the aging male population. PCa develops through dysregulation of androgen receptor (AR) signaling pathways. Despite improvements in diagnostic techniques and interventions, no pharmacological measures with long term efficacy have been established once PCa advances to castration resistant prostate cancer (CRPC). To circumvent this issue, tetra-aryl cyclobutanes (CBs) have been proposed as structurally distinct compounds with a mechanism of action differing from traditional androgen receptor signaling inhibitor (ARSIs). Here, we apply principles of crystal engineering and solid state synthesis to expand the class of CBs through strategic derivatization. The synthesis of the CB occurs quantitatively, producing no side products and eliminating the need for product purification. We demonstrate how head-to-tail stacking interactions of halo-pyrimidine rings can be exploited to stack and align unsymmetrical alkenes to undergo [2+2] photodimerization to generate the CB in the solid state. We examine the structure-function relationships of CBs in vitro by profiling AR mediated transcriptional activity, receptor translocation, and cell viability. Moreover, we explore and identify putative binding interactions within CB/AR complexes and establish an adaptive ligand-binding potential using molecular docking platforms. In total, our data suggests that CBs have unexploited therapeutic potential in CRPC and that green chemistry and crystal engineering principles offer a unique route to generating these drug candidates.
Open AccessProfiling crystal engineered ligands for targeting treatment resistant androgen receptors
Prostate cancer (PCa) is one of the principal contributors to health burden in the aging male population. PCa develops through dysregulation of androgen receptor (AR) signaling pathways. Despite improvements in diagnostic techniques and interventions, no pharmacological measures with long term efficacy have been established once PCa advances to castration resistant prostate cancer (CRPC). To circumvent this issue, tetra-aryl cyclobutanes (CBs) have been proposed as structurally distinct compounds with a mechanism of action differing from traditional androgen receptor signaling inhibitor (ARSIs). Here, we apply principles of crystal engineering and solid state synthesis to expand the class of CBs through strategic derivatization. The synthesis of the CB occurs quantitatively, producing no side products and eliminating the need for product purification. We demonstrate how head-to-tail stacking interactions of halo-pyrimidine rings can be exploited to stack and align unsymmetrical alkenes to undergo [2+2] photodimerization to generate the CB in the solid state. We examine the structure-function relationships of CBs in vitro by profiling AR mediated transcriptional activity, receptor translocation, and cell viability. Moreover, we explore and identify putative binding interactions within CB/AR complexes and establish an adaptive ligand-binding potential using molecular docking platforms. In total, our data suggests that CBs have unexploited therapeutic potential in CRPC and that green chemistry and crystal engineering principles offer a unique route to generating these drug candidates.
- Open Access
- 31 March 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (5) , 111415
Biosensor-guided discovery of peptide inhibitors targeting the ribosomal protein uS5-PDCD2 chaperone interaction
- 31 March 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (5) , 111415
Open AccessBiosensor-guided discovery of peptide inhibitors targeting the ribosomal protein uS5-PDCD2 chaperone interaction
- Open Access
Androgen Receptor Point Mutations: A Mechanism of Therapeutic Resistance and a Framework for Rational Drug Design
Background: Point mutations to the androgen receptor (AR) ligand-binding domain (LBD) are becoming increasingly recognized as a mechanism of therapeutic resistance in castration resistant prostate cancer (CRPC). The present review explores how point mutations induce molecular changes that contribute to the eventual treatment failure of androgen receptor pathway inhibitors (ARPIs) in CRPC. Methods: The PubMed database was searched for structural studies on the AR LBD. Eligible articles included molecular docking analysis and emphasized changes in ligand–receptor interactions after point mutation. Structural data were obtained from the Protein Data Bank (PDB) using the search parameters “Androgen receptor ligand binding domain”, “Homo sapiens”, and “X-ray diffraction”. PDB files of wild-type and point mutant AR LBDs were accumulated for analysis. Results: A functional shift from inhibiting to activating AR has been documented for multiple ARPIs. Crystallography data and in silico evaluation have deciphered how changes in steric hindrance of the AF-2 domain contribute to ARPI loss of function. To combat therapeutic resistance, discovery efforts have begun to consider combination approaches of orthosteric and allosteric inhibitors, as well as compounds that target other AR domains. Although lead compounds have been identified, none have progressed into the clinic. Conclusions: Questions remain regarding the best approach for rationally designing new AR targeting therapeutics. Understanding how structural changes to the AR LBD lead to the failure of clinical therapeutics is a necessary step that should precede drug discovery campaigns. Moreover, computational modeling is a powerful tool that should be leveraged to streamline therapeutic development.
Open AccessAndrogen Receptor Point Mutations: A Mechanism of Therapeutic Resistance and a Framework for Rational Drug Design
Background: Point mutations to the androgen receptor (AR) ligand-binding domain (LBD) are becoming increasingly recognized as a mechanism of therapeutic resistance in castration resistant prostate cancer (CRPC). The present review explores how point mutations induce molecular changes that contribute to the eventual treatment failure of androgen receptor pathway inhibitors (ARPIs) in CRPC. Methods: The PubMed database was searched for structural studies on the AR LBD. Eligible articles included molecular docking analysis and emphasized changes in ligand–receptor interactions after point mutation. Structural data were obtained from the Protein Data Bank (PDB) using the search parameters “Androgen receptor ligand binding domain”, “Homo sapiens”, and “X-ray diffraction”. PDB files of wild-type and point mutant AR LBDs were accumulated for analysis. Results: A functional shift from inhibiting to activating AR has been documented for multiple ARPIs. Crystallography data and in silico evaluation have deciphered how changes in steric hindrance of the AF-2 domain contribute to ARPI loss of function. To combat therapeutic resistance, discovery efforts have begun to consider combination approaches of orthosteric and allosteric inhibitors, as well as compounds that target other AR domains. Although lead compounds have been identified, none have progressed into the clinic. Conclusions: Questions remain regarding the best approach for rationally designing new AR targeting therapeutics. Understanding how structural changes to the AR LBD lead to the failure of clinical therapeutics is a necessary step that should precede drug discovery campaigns. Moreover, computational modeling is a powerful tool that should be leveraged to streamline therapeutic development.
- 16 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (3) , 2063-2081
Tunable Biased Signaling of the Angiotensin II Type 1 Receptor for Inotropy via C-Terminal Peptide Engineering and Allosteric Site Targeting
The angiotensin II (AngII) type 1 receptor (AT1R) is a key prototypical G protein-coupled receptor in cardiovascular regulation. Biased agonists activating G protein or β-arrestin pathways offer therapeutic promise, but the molecular determinants of this signaling bias and its physiological implications remain poorly understood. This study profiles AngII analogs with C-terminal Phe8 modifications, identifies compounds 11, 12, and 29a as exhibiting differential Gαq activation while retaining potent β-arrestin recruitment. Notably, 12 with low levels of Gαq activity, enhances left ventricular ejection fraction with limited pressor responses in normotensive rats. In contrast, other analogs with variably superior Gαq activity do not promote inotropy. Molecular modeling suggests that the flexible side chain of 12 accesses a deep allosteric pocket within AT1R, driving its unique signaling profile. This study demonstrates that engineering AngII's C-terminus enables selective tuning of AT1R signaling to control arterial versus cardiac responses, providing strategies for developing improved cardiovascular therapeutics.
- 16 January 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (3) , 2063-2081
Tunable Biased Signaling of the Angiotensin II Type 1 Receptor for Inotropy via C-Terminal Peptide Engineering and Allosteric Site Targeting
The angiotensin II (AngII) type 1 receptor (AT1R) is a key prototypical G protein-coupled receptor in cardiovascular regulation. Biased agonists activating G protein or β-arrestin pathways offer therapeutic promise, but the molecular determinants of this signaling bias and its physiological implications remain poorly understood. This study profiles AngII analogs with C-terminal Phe8 modifications, identifies compounds 11, 12, and 29a as exhibiting differential Gαq activation while retaining potent β-arrestin recruitment. Notably, 12 with low levels of Gαq activity, enhances left ventricular ejection fraction with limited pressor responses in normotensive rats. In contrast, other analogs with variably superior Gαq activity do not promote inotropy. Molecular modeling suggests that the flexible side chain of 12 accesses a deep allosteric pocket within AT1R, driving its unique signaling profile. This study demonstrates that engineering AngII's C-terminus enables selective tuning of AT1R signaling to control arterial versus cardiac responses, providing strategies for developing improved cardiovascular therapeutics.
- Open Access
- 31 December 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (4) , 2396-2419
A neurotensin receptor type 1-derived pepducin acts as a biased allosteric modulator to regulate target receptor function
- 31 December 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (4) , 2396-2419
Open AccessA neurotensin receptor type 1-derived pepducin acts as a biased allosteric modulator to regulate target receptor function
- Open Access
Identification of skeletal muscle stem cell adhesion motifs using spot-synthesis-based peptide arrays
- Open Access
- 12 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Structure-based design of macrocyclic peptides to generate functional antibodies against G protein-coupled receptors
G protein-coupled receptors (GPCRs) are critical to a variety of pathophysiological processes, making them attractive targets for the development of drugs or relevant diagnostic tools. Although GPCRs have been successfully targeted with small molecules, the production of reliable anti-GPCR antibodies remains a major challenge. To address this issue, we develop a strategy using macrocyclic peptides designed to mimic the three-dimensional structure of GPCR extracellular loops as immunogens and use the chicken, which is genetically distant from mammals, as an immunization host to produce antigen-specific antibodies. The high-affinity neurotensin receptor type 1 (NTS1), overexpressed in many types of human cancer and associated with poor prognosis, is used as a target. Rational design of macrocyclic epitope mimics and linker selection are achieved using modeling and predictive analysis software tools based on available NTS1 crystal structures. This study particularly highlights the critical role of the linker in peptide macrocyclization, which determines whether antibodies can exert antagonistic activity. Overall, this strategy represents a valuable asset to produce effective spatial anti-GPCR antibodies and holds promise for diagnostic and therapeutic applications.
- 12 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Open AccessStructure-based design of macrocyclic peptides to generate functional antibodies against G protein-coupled receptors
G protein-coupled receptors (GPCRs) are critical to a variety of pathophysiological processes, making them attractive targets for the development of drugs or relevant diagnostic tools. Although GPCRs have been successfully targeted with small molecules, the production of reliable anti-GPCR antibodies remains a major challenge. To address this issue, we develop a strategy using macrocyclic peptides designed to mimic the three-dimensional structure of GPCR extracellular loops as immunogens and use the chicken, which is genetically distant from mammals, as an immunization host to produce antigen-specific antibodies. The high-affinity neurotensin receptor type 1 (NTS1), overexpressed in many types of human cancer and associated with poor prognosis, is used as a target. Rational design of macrocyclic epitope mimics and linker selection are achieved using modeling and predictive analysis software tools based on available NTS1 crystal structures. This study particularly highlights the critical role of the linker in peptide macrocyclization, which determines whether antibodies can exert antagonistic activity. Overall, this strategy represents a valuable asset to produce effective spatial anti-GPCR antibodies and holds promise for diagnostic and therapeutic applications.